UDI Data Submission Case Study: Henry Schein

September 30, 2016 Daniel Henrich

As Henry Schein evaluated the FDA’s requirements for Unique Device Identification (UDI), Jeff Peacock, VP of Global Quality Assurance and Regulatory Affairs, realized he and his team had a daunting task ahead of them. Henry Schein manages the distribution of approximately 100,000 different medical device SKUs in the United States, with roughly 10,000 of those bearing a Henry Schein label.

Each record in GUDID, the FDA’s UDI database, is made up of 62 data fields. Since Henry Schein acts as distributor for a very large network of device manufacturers, it is ultimately responsible to the FDA as the labeler of products bearing the Henry Schein name.

“There is no other label on the product except ours,” says Peacock, so responsibility for submission to the GUDID rests with his department. “The unique challenge is that the majority of the data are maintained by the OEM manufacturer.”

 

As the Henry Schein team was faced with collecting, normalizing, submitting and maintaining all of this data for each product in U.S. distribution, they realized the process would be extremely time consuming and at high risk for error. Not only was it necessary to collect hundreds of thousands of data fields, but each manufacturer stored and formatted the data differently. All entries would need to be collected, standardized and checked against company records and FDA business rules. To get started, Henry Schein needed to determine a method for managing and submitting this high volume of data to the FDA.

This is an excerpt from a larger case study. You can access the full document here

The opinions expressed within this case study represent customer opinions. LexisNexis believes this case study experience generally represents the experience found with other similar customer situations. However, each customer will have its own subjective goals and requirements and will subscribe to different combinations of LexisNexis services to suit those specific goals and requirements. This case study may not be deemed to create any warranty or representation that any other customer’s experience will be the same as the experience identified herein. LexisNexis uses the customer’s trademarks herein with the customer’s permission.

Previous Article
Drug Establishment Registration Reporting Requirements and Timelines
Drug Establishment Registration Reporting Requirements and Timelines

Every electronic drug establishment registration must be renewed or updated annually between October 1 and ...

Next Article
Better Patent Prosecution with Data Analytics
Better Patent Prosecution with Data Analytics

Patent practitioners are still grappling with the fallout from the Supreme Court’s decision in Alice v. CLS...

Need additional information?

Contact Us